Adaptive Biotechnologies provides a CLIA‑certified, NGS‑based minimal residual disease assay (clonoSEQ) with sensitivity to 10⁻⁶ and high‑coverage T‑cell and B‑cell receptor immunosequencing that generates >10⁶ clonotypes per sample. The resulting repertoire data are processed through proprietary bioinformatics pipelines and delivered via secure cloud dashboards and API endpoints for clinical laboratories, trial sponsors, and biopharma drug‑discovery programs.
Funding
$125M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Accurate detection of minimal residual disease (MRD) and identification of disease‑specific immune receptor signatures are limited by conventional assays that lack the sensitivity, scalability, and molecular depth required for modern oncology and immunotherapy development.
Solution
Adaptive Biotechnologies leverages its Immune Medicine Platform to decode the adaptive immune repertoire using high‑throughput next‑generation sequencing (NGS). The platform delivers a clinically validated MRD assay (clonoSEQ) that quantifies residual malignant clones with single‑cell resolution, enabling precise treatment decisions in hematologic cancers. In parallel, the company provides T‑cell receptor (TCR) and B‑cell receptor (BCR) immunosequencing services that generate comprehensive repertoire datasets for target discovery, antigen mapping, and therapeutic design. These data are processed through proprietary bioinformatics pipelines and made available via secure cloud dashboards and API endpoints, supporting both diagnostic workflows and drug‑discovery programs. By turning the immune system’s natural coding language into actionable molecular information, the platform bridges the gap between disease detection and the development of TCR‑ and antibody‑based therapeutics.
Target Audience
Primary customers are hematology/oncology laboratories and clinical trial sponsors requiring high‑sensitivity MRD testing, as well as biopharma companies and biotech developers seeking immunosequencing data for TCR/antibody therapeutic discovery and target validation.
Features
- CLIA‑certified, NGS‑based MRD assay (clonoSEQ) with sensitivity down to 10⁻⁶, supporting both clinical practice and trial enrollment.
- High‑coverage TCR and BCR immunosequencing (Adaptive Immunosequencing) delivering >10⁶ unique clonotypes per sample.
- Proprietary antigen‑mapping pipeline that links public TCR signatures to specific pathogens or tumor antigens using a curated reference database.
- Cloud‑hosted analytics suite with longitudinal repertoire tracking, clonality metrics, and customizable visualizations accessible via web UI or FHIR‑compatible API.
- End‑to‑end data security and compliance (HIPAA, GDPR) with role‑based access controls and encrypted data transfer.
- Pharma services including custom sequencing projects, target discovery consulting, and collaborative therapeutic development for TCR and antibody modalities.
- Integrated workflow tools for clinical trial sponsors to monitor MRD dynamics and immune response biomarkers in real time.